## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

## **LISTING OF CLAIMS:**

- 1-30. (canceled).
- (previously presented) An isolated monoclonal antibody MJ-170 produced by hybridoma cell line MJ-170 on deposit with the American Type Culture Collection (ATCC) as accession number PTA-5286.
- (previously presented) An isolated monoclonal antibody MJ-171 produced by 2-32. hybridoma cell line MJ-171 on deposit with the ATCC as accession number PTA-5287.
- (previously presented) An isolated monoclonal antibody MJ-172 produced by 3 23. hybridoma cell line MJ-172 on deposit with the ATCC as accession number PTA-5288.
- (previously presented) An isolated monoclonal antibody MJ-173 produced by 4-34. hybridoma cell line MJ-173 on deposit with the ATCC as accession number PTA-5302.
- (previously presented) A hybridoma cell line MJ-170 on deposit with the ATCC 5 23. as accession number PTA-5286.
- (previously presented) A hybridoma cell line MJ-171 on deposit with the ATCC 6 36. as accession number PTA-5287.
- (previously presented) A hybridoma cell line MJ-172 on deposit with the ATCC 7 37. as accession number PTA-5288.
- (previously presented) A hybridoma cell line MJ-173 on deposit with the ATCC as accession number PTA-5302.
  - 39. (canceled).
- (previously presented) An antibody of claim 31, 32, 33 or 34, wherein said 9 40. antibody is covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.
- (previously presented) The antibody of claim 40, wherein said cytotoxic agent is a small drug molecule.

(previously presented) The antibody of claim 40, wherein said cytotoxic agent is a maytansinoid, a taxoid, or a CC-1065 analog.

(original) A composition comprising an antibody of claim 37,32,33 or 34 and a pharmaceutically acceptable carrier.

(previously presented) A composition comprising the antibody of claim 40 and a pharmaceutically acceptable carrier.

(withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim 43.12

(withdrawn) A method of treating a subject having a cancer, comprising administering to a subject having a cancer a therapeutically effective amount of the composition of claim 44.

47-48. (canceled).

(withdrawn) The method of claim 45, wherein said cancer is a cancer wherein

Muc1 or Muc16 is overexpressed.

15

(withdrawn) The method of claim 46, wherein said cancer is a cancer wherein

Muc1 or Muc16 is overexpressed.

(withdrawn) The method of claim 45, wherein said cancer is ovarian cancer or breast cancer.

(withdrawn) The method of claim 46, wherein said cancer is ovarian cancer or breast cancer.

20 53. (previously presented) An isolated antibody that specifically binds to a Mucl peptide selected from the group consisting of:

- a) QLTLAFREGTINVHDVETQFN (SEQ ID NO:8);
- b) QYKTEAASRYNLTISDVSVSD (SEQ ID NO:9);
- c) FLQIYKQGGFLGLSNIKFRPG (SEQ ID NO:10); and
- d) VPFPFSAQSGAGVPGWGIA (SEQ ID NO:12).

21 54. (previously presented) An isolated antibody that specifically binds to a Muc16 peptide selected from the group consisting of:

	•			
a)	SSVLVDGYSPNRNEPLTGNS	(SEQ ID NO:14);		
b) .	TNYQRNKRNIEDALNQLFRN	(SEQ ID NO:15);		
c)	FRNSSIKSYFSDCQVSTFRSV	(SEQ ID NO:16);		
d)	SVPNRHHTGVDSLCNFSPLARRV	(SEQ ID NO:17); and		
e)	DRVAIYEEFLRMTRNGTQLQNFTLDRSS	(SEQ ID NO:18).		
22 55	(currently amended) The antibody of claim 33 or			
selected from the group consisting of a monoclonal antibody, a recombinant antibody, an				
antigen-binding a-fragment of a recombinant antibody, a humanized antibody, and an antibody				
• •	on the surface of a phage.	) 31		
23 -56.	(previously presented) The antibody of claim 53	or,54, wherein said antibody is		
covalently linked to a cytotoxic agent or a prodrug of a cytotoxic agent.				
24 -ST.	(previously presented) The antibody of claim 36	, wherein said cytotoxic agent is		
a small drug molecule.  23  (previously presented) The antibody of claim 56, wherein said cytotoxic agent is				
25 -58.	(previously presented) The antibody of claim 56	, wherein said cytotoxic agent is		
o moutonsino	id, taxoid, or CC-1065 analog.	_		
		20 21		
26 ×59.	(previously presented) A composition comprising acceptable carrier.			
26 ~59. and a pharma	(previously presented) A composition comprising acceptable carrier.	ng the antibody of claim 53 or 54		
26, 59. and a pharma 27, 66.	(previously presented) A composition comprising	ng the antibody of claim 53 or 54		
26 -59. and a pharma 27 -60. pharmaceutic	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising acceptable carrier.	ng the antibody of claim 53 or 54 ag the antibody of claim 56 and a		
26 /59. and a pharma 27 /60. pharmaceutic	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising	ng the antibody of claim 53 or 54 and a g the antibody of claim 56 and a ng a cancer, comprising		
26 /59. and a pharma 27 /60. pharmaceutic	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising a cally acceptable carrier.  (withdrawn) A method of treating a subject having	ng the antibody of claim 53 or 54 and a g the antibody of claim 56 and a ng a cancer, comprising		
and a pharma  27 60.  pharmaceutic  28 61.  administering  of claim 59.	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising a cally acceptable carrier.  (withdrawn) A method of treating a subject having	ig the antibody of claim 53 or 54 and a general sective amount of the composition		
and a pharma  27 60.  pharmaceutic  28 61.  administering  of claim 59.  29 62.  administering	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising ally acceptable carrier.  (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effects (withdrawn) A method of treating a subject having a cancer a therapeutically effects to a subject having a cancer a therapeutically effects to a subject having a cancer a therapeutically effects to a subject having a cancer a therapeutically effects.	ig the antibody of claim 53 or 54 ag the antibody of claim 56 and a ang a cancer, comprising ctive amount of the composition ang a cancer, comprising		
and a pharma  27 66.  pharmaceutic  28 61.  administering  of claim 59.  29 62.  administering	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising a cally acceptable carrier.  (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect (withdrawn) A method of treating a subject having a cancer a therapeutically effect to a subject having a cancer a therapeutically effect to a subject having a cancer a therapeutically effect to a subject having a cancer a therapeutically effects.	ig the antibody of claim 53 or 54 and a grant and a gr		
and a pharma  27 66.  pharmaceutic  28 61.  administering  of claim 59.  29 62.  administering	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising a cally acceptable carrier.  (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect (withdrawn) A method of treating a subject having a cancer a therapeutically effect to a subject having a cancer a therapeutically effect to a subject having a cancer a therapeutically effect to a subject having a cancer a therapeutically effects.	ig the antibody of claim 53 or 54 and a grant and a gr		
and a pharma  27 60.  pharmaceutic  28 61.  administering  of claim 59.  29 62.  administering  of claim 60.  30 63.  Mucl or Mucl	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising cally acceptable carrier.  (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect to a subject having	ig the antibody of claim 53 or 54 ag the antibody of claim 56 and a ang a cancer, comprising ctive amount of the composition are cancer, comprising ctive amount of the composition aid cancer is a cancer wherein		
and a pharma  27 60.  pharmaceutic  28 61.  administering  of claim 59.  29 62.  administering  of claim 60.  30 63.  Mucl or Mucl	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising cally acceptable carrier.  (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect to a subject having	ig the antibody of claim 53 or 54 ag the antibody of claim 56 and a ang a cancer, comprising ctive amount of the composition are cancer, comprising ctive amount of the composition aid cancer is a cancer wherein		
and a pharma  27 66.  pharmaceutic  28 61.  administering  of claim 59.  29 62.  administering  of claim 60.  30 63.  Mucl or Mucl  31 64.	(previously presented) A composition comprising acceptable carrier.  (previously presented) A composition comprising cally acceptable carrier.  (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect (withdrawn) A method of treating a subject having to a subject having a cancer a therapeutically effect to a subject having	ig the antibody of claim 53 or 54 ag the antibody of claim 56 and a ang a cancer, comprising ctive amount of the composition are cancer, comprising ctive amount of the composition aid cancer is a cancer wherein		

28 29

- 32 65. (withdrawn) The method of claim 61 or 62, wherein said cancer is ovarian cancer or breast cancer.
- 33 66. (withdrawn) A method of screening a subject for cancer, comprising:
- (a) measuring the amount of Mucl in a biological sample obtained from a subject using the antibody of claim 53, and
- (b) comparing the amount of Muc1 measured in (a) to the amount of Muc1 in a cancerous and a non-cancerous control, thereby screening a subject for cancer.
- 34 67. (withdrawn) A method of screening a subject for cancer, comprising:
- (a) measuring the amount of Muc16 in a biological sample obtained from a subject using the antibody of claim, 31; and
- (b) comparing the amount of Muc16 measured in (a) to the amount of Muc16 in a cancerous and a non-cancerous control, thereby screening a subject for cancer.
- 35 68. (withdrawn) The method of claim 66 or 67, wherein said cancer is ovarian cancer or breast cancer.
  - 69-70. (canceled).
- 36 A. (previously presented) A hybridoma that produces an antibody that specifically binds to a MUC1 peptide selected from the group consisting of:
  - a) QLTLAFREGTINVHDVETQFN (SEQ ID NO:8);
  - b) OYKTEAASRYNLTISDVSVSD (SEQ ID NO:9);
  - c) FLQIYKQGGFLGLSNIKFRPG (SEQ ID NO:10); and
  - d) VPFPFSAQSGAGVPGWGIA (SEQ ID NO:12).
- 37.72. (previously presented) A hybridoma that produces an antibody that specifically binds to a MUC16 peptide selected from the group consisting of:

a)	SSVLVDGYSPNRNEPLTGNS	(SEQ ID NO:14);
b)	TNYQRNKRNIEDALNQLFRN	(SEQ ID NO:15);
c)	FRNSSIKSYFSDCQVSTFRSV	(SEQ ID NO:16);
d)	SVPNRHHTGVDSLCNFSPLARRV	(SEQ ID NO:17); and
e)	DRVAIVEFFLRMTRNGTOLONFTLDRSS	(SEO ID NO:18).